Navigation Links
Actavis First Quarter 2013 Net Revenue Increases 24% to $1.9 Billion
Date:5/2/2013

d to the prior year period. Anda Distribution segment revenue consists only of sales of third-party products and excludes sales of Actavis' brand and generic products.

Anda Distribution segment gross margin increased approximately 4 percentage points to 15.8 percent in the first quarter of 2013, primarily due to lower chain sales in the current year.

Other Operating Expenses
Consolidated GAAP general and administrative expenses were $185.8 million in the first quarter 2013, an increase of $21.4 million from the first quarter 2012 as a result of the acquisition, integration and restructuring charges associated with the acquisitions of Actavis and Uteron and higher expenses associated with the addition of the legacy Actavis business. General and administrative expenses in the prior year were impacted by a $59.8 million litigation charge primarily related to the Company's drug pricing litigation.

Amortization expense for the first quarter 2013 was $158.4 million, compared to $131.9 million in first quarter 2012.

2013 Financial Outlook 
Actavis' estimates are based on actual results for the first quarter of 2013 and management's current belief about prescription trends, pricing levels, inventory levels and the anticipated timing of future product launches and events. 

Actavis estimates total net revenue for 2013 of approximately $8.1 billion.

  • Total Actavis Pharma segment revenue of between $6.3 billion and $6.5 billion.
  • Total Actavis Specialty Brands segment revenue of between $550 million and $600 million.
  • Total Anda Distribution segment revenue of between $1.0 billion and $1.2 billion.
  • Adjusted non-GAAP earnings for 2013 is expected to be between $8.10 and $8.50 per diluted share.
  • Adjusted EBITDA for 2013 is expected to be between $1.95 billion and $2.03 billion.
  • Webcast and Conference Call Details
    Actavis will host a conference call and webcast today
    '/>"/>

    SOURCE Actavis, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

    Related medicine technology :

    1. Actavis Acquires Worldwide Rights for Valeants Metronidazole 1.3% Vaginal Gel
    2. Actavis, Inc. to Host First Quarter 2013 Earnings Conference Call and Webcast
    3. Former Clinton Deputy Solicitor General sheds light on flaws in Federal Trade Commissions case in FTC v. Actavis Inc.
    4. Actavis, Inc. to Present at the Barclays 2013 Global Healthcare Conference
    5. Actavis, Inc. to Present at the Cowen & Company 33rd Annual Health Care Conference
    6. Actavis Full Year 2012 Net Revenue Increases 29% to $5.91 Billion
    7. Actavis, Inc. to Present at the RBC Capital Markets Healthcare Conference
    8. Actavis, Inc. to Host Fourth Quarter 2012 Earnings Conference Call and Webcast
    9. Watson Pharmaceuticals, Inc. is Now Actavis, Inc.
    10. Watson Announces New Name -- Actavis -- for Global Operations
    11. Watson and Actavis Receive FTC Second Request
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/18/2014)... ARBOR, Mich. , Sept. 18, 2014  A ... Research will allow the University of Michigan to establish ... The Glenn Center for Aging Research at ... evidence that drugs can slow the effects of aging ... unlock mechanisms of aging that can help develop medications ...
    (Date:9/18/2014)... SAN DIEGO , Sept. 18, 2014 /PRNewswire/ ... today announced that the U.S. Food and Drug ... patient enrollment and dosing of PEGPH20 in SWOG,s ... is designed to evaluate Halozyme,s investigational drug PEGPH20 ... FOLFIRINOX chemotherapy (mFOLFIRINOX) in patients with metastatic pancreatic ...
    (Date:9/18/2014)... -- Australian biomarker discovery company Minomic International Ltd will ... prostate cancer screening test, planning to achieve US Food ... Minomic,s proprietary MiStat™ technology is a screening assay ... known as the MIL-38 antigen. This biomarker is present ... Researchers at 11 leading urology centres in ...
    Breaking Medicine Technology:$3 M grant funds Paul F. Glenn Center for Aging Research at the University of Michigan 2$3 M grant funds Paul F. Glenn Center for Aging Research at the University of Michigan 3SWOG To Resume Clinical Trial Of Halozyme's PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer 2SWOG To Resume Clinical Trial Of Halozyme's PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer 3SWOG To Resume Clinical Trial Of Halozyme's PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer 4Minomic Launches US Pilot Study of MiStat(TM) Novel Prostate Cancer Screening Technology 2
    ... , ALLEGAN, Mich. , Jan. 19 ... release financial results for its second quarter fiscal 2010 on Tuesday, ... Company will conduct a conference call at 10:00 a.m. (ET) ... Officer. , The conference call will be available live via webcast to ...
    ... LAKE CITY , Jan. 19 World Heart ... circulatory systems, announced today that the first U.S. implant of ... INTEGRIS Baptist Medical Center ("INTEGRIS") in Oklahoma City ... the first implant in the Levacor VAD bridge-to-transplant ("BTT") study, ...
    Cached Medicine Technology:Perrigo Company Will Release Second Quarter Fiscal 2010 Results on February 2, 2010 2WorldHeart Announces First U.S. Implant of Levacor(TM) VAD Implant at INTEGRIS in Oklahoma City 2WorldHeart Announces First U.S. Implant of Levacor(TM) VAD Implant at INTEGRIS in Oklahoma City 3
    (Date:9/18/2014)... Throughout their lives, sisters support each other. ... their achievements and accomplishments together, and lend helping hands. ... Joanie’s Sisters in Support, a support sorority, does all ... their battles against breast and ovarian cancers – a ... in June, meets once a month at the Joanie ...
    (Date:9/18/2014)... professor Robert Campbell (Ophthalmology) has revealed using anti-inflammatory medications ... Glaucoma is the most common cause of irreversible blindness ... with the disease, which is mainly caused by pressure ... optic nerve. The optic nerve is responsible for sending ... a vital part of vision., "The use of strong ...
    (Date:9/18/2014)... Massachusetts, U.S.A., September 18, 2014 -- BGI Tech ... service to Denmark-based DLF-Trifolium and the Department of ... in an effort to develop a series of ... selection (GS) methods. , GS is a new ... to the traditional QTL-based selection, uses information equally ...
    (Date:9/18/2014)... 18, 2014 Good Neighbor Pharmacy, ... of Good Neighbor Pharmacy University, an online central ... will educate and empower pharmacy owners and their ... industry continues to evolve, Good Neighbor Pharmacy is ... resources and tools to help their businesses thrive,” ...
    (Date:9/18/2014)... new expert panel report, Improving Medicines for Children ... Canadian Academies, addresses the importance of developing safe ... half of Canada,s seven million children use at ... is done off-label (i.e. the prescription differs from ... have historically been excluded in drug research and ...
    Breaking Medicine News(10 mins):Health News:Artist’s Cancer Jewelry to Benefit Joanie’s Sisters 2Health News:Artist’s Cancer Jewelry to Benefit Joanie’s Sisters 3Health News:BGI Tech, DLF-Trifolium A/S, and Aarhus University applying genomic selection methods 2Health News:Good Neighbor Pharmacy University Keeps Pharmacists Ahead of the Curve 2Health News:Improving medicines for children in Canada 2
    ... ... the opening keynote address to more than 8,000 professionals from the biopharmaceutical and related sectors ... ... Margaret Hamburg, Commissioner of the US Food and Drug Administration (FDA), will deliver the opening ...
    ... 4 Sixty-one-year old Joanne Bogan is being treated for two ... living with multiple sclerosis. Both are healthier today thanks to ... its innovative model of care. The ground-breaking story of Eleventh ... today by the Center to Champion Nursing in America ...
    ... NEW YORK, Nov. 4 Today, St. Jude Children,s Research ... campaign, an unprecedented union of celebrities, media, retail and corporate ... kids in your life, and give to those who are ... , national outreach director for St. Jude. , For ...
    ... Celsius Holdings, Inc. (OTC Bulletin Board:CSUH.OB), maker of Celsius®, ... host a conference call on Tuesday, November 10, 2009, beginning ... quarter 2009 financial results. The call will be open to ... will provide opportunity for real time questions and answers. , ...
    ... family size increases, study finds, , WEDNESDAY, Nov. 4 (HealthDay ... having kids. , A new study found that having children ... But unmarried couples shouldn,t expect to find greater happiness through ... of the Journal of Happiness Studies , suggests that ...
    ... DIEGO, Nov. 4 NovaRx Corporation announced today that ... for a Special Protocol Assessment (SPA) Protocol Amendment to ... with Non-Small Cell Lung Cancer (NSCLC). The amendment will ... patients with stable brain metastases. As many as one ...
    Cached Medicine News:Health News:FDA Commissioner Margaret Hamburg to Deliver Keynote Address at DIA 46th Annual Meeting, June 13-17, 2010 in Washington, DC , 2Health News:FDA Commissioner Margaret Hamburg to Deliver Keynote Address at DIA 46th Annual Meeting, June 13-17, 2010 in Washington, DC , 3Health News:Drexel University's Eleventh Street Health Services Recognized as National Model of Innovative Health Care 2Health News:Stars of Film, Television, Sports and Music Join Marlo Thomas to Kick Off the 6th Annual Thanks and Giving(R) Campaign to Support St. Jude Children's Research Hospital(R) 2Health News:Stars of Film, Television, Sports and Music Join Marlo Thomas to Kick Off the 6th Annual Thanks and Giving(R) Campaign to Support St. Jude Children's Research Hospital(R) 3Health News:Stars of Film, Television, Sports and Music Join Marlo Thomas to Kick Off the 6th Annual Thanks and Giving(R) Campaign to Support St. Jude Children's Research Hospital(R) 4Health News:Stars of Film, Television, Sports and Music Join Marlo Thomas to Kick Off the 6th Annual Thanks and Giving(R) Campaign to Support St. Jude Children's Research Hospital(R) 5Health News:Celsius Holdings, Inc. Invites You to Join its Third Quarter 2009 Financial Results Conference Call on Tuesday, November 10, 2009, at 4:30 p.m. Eastern 2Health News:Married With Children Paves Way to Happiness 2Health News:NovaRx Corporation Announces FDA Approval of Protocol Amendment to Special Protocol Assessment (SPA) for Phase III Lucanix(R) Study in Non-Small Cell Lung Cancer (NSCLC) 2Health News:NovaRx Corporation Announces FDA Approval of Protocol Amendment to Special Protocol Assessment (SPA) for Phase III Lucanix(R) Study in Non-Small Cell Lung Cancer (NSCLC) 3
    Straight shafts with 0.5 mm teeth and 6 mm tying platform. Wide serrated handle with thumb catch lock and polished finish....
    Straight shafts with 0.12 mm teeth and tying platform. Serrated handle with polished finish....
    Heavy curved shafts with 2 x 2 teeth and crisscross serrated 6 mm tying platform. Serrated handle with polished finish....
    Straight shafts with 5.5 mm tying platform. 0.3 mm gap at platform heel. True round knurled handle in the closed position. Polished finish. Tips: 0.12 mm teeth....
    Medicine Products: